PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

All trades: Syncona announces sale of portfolio company to Novartis

Syncona – a company focused on founding, building and funding global leaders in life science – has announced the sale of its portfolio company, Gyroscope Therapeutics Holdings plc.

The company has been sold to Novartis, for up to $1.5 billion (£1.1 billion). The upfront cash payment of $800 million (£587 million) has been paid, and up to $700 million (£514 million) in cash is due upon reaching certain milestones.

The transaction generates upfront cash proceeds of $442 million (£325 million) for Syncona’s holding in Gyroscope, which strengthens Syncona’s capital base, as it continues to build and fund its portfolio of life science companies.

Syncona will continue to value the milestone payments, and their risk-adjusted and discounted valuation of these payments for its holding in Gyroscope is estimated to be $64 million (£47 million).

The company aims to found and build companies to deliver transformational treatments to patients in areas of high unmet need. The company’s strategy is to found, build, and fund companies around exceptional science to create a diversified portfolio of 15-20 globally leading healthcare businesses for the benefit of all stakeholders.

The business was set up to address the absence of long-term funding in UK life science, through creating globally competitive, sustainable companies. Syncona’s balance sheet underpins their strategy, allowing them to take a long-term view as we look to improve the lives of patients with no or poor treatment options, build sustainable life science companies, and deliver strong risk-adjusted returns to shareholders.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026